Cox-2 inhibitor

(redirected from COX-2-selective inhibitors)
Also found in: Thesaurus, Medical, Encyclopedia.

COX-2 inhibitor

Any of a class of nonsteroidal anti-inflammatory drugs that selectively block prostaglandin formation so as to cause minimal gastrointestinal side effects.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Cox-2 inhibitor - an anti-inflammatory drug that fights pain and blocks Cox-2 activity without impeding the activity of Cox-1; increases the risk of heart attacks; "Cox-2 inhibitors reduce the symptoms of arthritis without endangering the stomach and kidneys"
anti-inflammatory, anti-inflammatory drug - a medicine intended to reduce inflammation
Celebrex, celecoxib - a Cox-2 inhibitor (trade name Celebrex) that relieves pain and inflammation without harming the digestive tract
rofecoxib, Vioxx - a Cox-2 inhibitor (trade name Vioxx) that relieves pain and inflammation without harming the digestive tract; voluntarily withdrawn from the market in 2004
Bextra, valdecoxib - a Cox-2 inhibitor (trade name Bextra) that relieves pain and inflammation without harming the digestive tract
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
Several classes of COX-2-selective inhibitors have been identified, including the diarylheterocyclics (or tricyclics), acidic sulfonamides, and 2,6-ditert-butyl phenols, as well as the derivatives of the nonselective inhibitors zomepirac, indomethacin, piroxicam, and aspirin [88-90].
This researcher therefore suggested that factors to consider for patient safety include the direct effects of nonselective NSAIDs and of COX-2-selective inhibitors on fluid retention and blood pressure, differences among these agents with regard to associated gastrointestinal adverse event rates and the utility of simultaneous anti-inflammatory therapies with gastroprotective agents such as proton pump inhibitors when patients require cardioprotective doses of aspirin.
The risks for GI damage associated with the use of NS-NSAIDs has been somewhat mitigated by the availability of COX-2-selective inhibitors and by proton pump inhibitors.